Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (16668)	3/6/1998 10:23:00 PM
From: Henry Niman	Respond to of 32384

PB, I'm still trying to find the summary, but I think that DR in his talk or breakout session, mentioned that SBH may be putting a compound into the clinic this year, and my recollection was that the small molecule would either mimic EPO or GM-CSF.

To: Pseudo Biologist who wrote (16668)	3/6/1998 10:37:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's what LGND said a year ago about progress on mimics for EPO and GM-CSF: SmithKline Beecham Expands Collaboration We have made significant progress in our partnership with SmithKline Beecham to discover orally active small molecule mimics and potentiators for hematopoietic growth factors. During 1996 we screened compounds and identified several distinct leads which have interesting activity. We are working toward selection of a single lead compound in 1997. The initial focus of the collaboration is on the discovery of small molecule drugs to enhance hematopoiesis (formation and development of blood cells) in a variety of anemias and after cancer therapy. Based on the success of this work, SmithKline Beecham elected to expand the scope of the collaboration to include a program to discover small molecules to stimulate blood platelet production. This event triggered a $2.5 million milestone payment during the first quarter of 1997.